Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

A team of scientists is investigating a new type of antibody, which stimulates the immune system to target cancer cells an ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.